Denali Therapeutics Stock Current Asset

DNLI Stock  USD 27.59  0.17  0.62%   
Denali Therapeutics fundamentals help investors to digest information that contributes to Denali Therapeutics' financial success or failures. It also enables traders to predict the movement of Denali Stock. The fundamental analysis module provides a way to measure Denali Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Denali Therapeutics stock.
The Denali Therapeutics' current Non Current Assets Total is estimated to increase to about 154.9 M, while Other Current Assets are projected to decrease to under 18.9 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Denali Therapeutics Company Current Asset Analysis

Denali Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Current Asset

 = 

Cash

+

Deposits

+

Liquid Assets

More About Current Asset | All Equity Analysis

Current Denali Therapeutics Current Asset

    
  281.74 M  
Most of Denali Therapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Denali Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Denali Current Asset Historical Pattern

Today, most investors in Denali Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Denali Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Denali Therapeutics current asset as a starting point in their analysis.
   Denali Therapeutics Current Asset   
       Timeline  
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition

Denali Total Assets

Total Assets

932.84 Million

As of now, Denali Therapeutics' Total Assets are increasing as compared to previous years.
In accordance with the recently published financial statements, Denali Therapeutics has a Current Asset of 281.74 M. This is 86.91% lower than that of the Biotechnology sector and 73.44% lower than that of the Health Care industry. The current asset for all United States stocks is 96.98% higher than that of the company.

Denali Current Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Denali Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics of similar companies.
Denali Therapeutics is currently under evaluation in current asset category among its peers.

Denali Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Denali Therapeutics from analyzing Denali Therapeutics' financial statements. These drivers represent accounts that assess Denali Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Denali Therapeutics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap1.9B1.7B9.1B3.5B2.9B2.2B
Enterprise Value1.8B1.7B8.7B3.3B2.9B2.1B

Denali Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Denali Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Denali Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

Denali Fundamentals

About Denali Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:
Check out Denali Therapeutics Piotroski F Score and Denali Therapeutics Altman Z Score analysis.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.86)
Revenue Per Share
0.009
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.22)
Return On Equity
(0.33)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.